GlassScriptPhysician profile
Elena Resnick
NPI 1861659187
$1,066.06
in general payments reported to CMS, 2019-2025
20 companies · $97.35 in 2025
The $97.35 reported for 2025 was less than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $51.10 · 2020: $49.83 · 2021: $215 · 2022: $116 · 2023: $363 · 2024: $174 · 2025: $97.35.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $634.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $634.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $145.40 | 2022-2024 | Xifaxan, Trulance |
| Idorsia Pharmaceuticals US INC | $127.11 | 2022-2023 | Quviviq |
| Genzyme Corporation | $103.85 | 2019-2025 | |
| Glaxosmithkline, LLC. | $74.65 | 2021-2024 | Trelegy Ellipta |
| Regeneron Healthcare Solutions, INC. | $73.72 | 2023-2025 | Dupixent |
| Janssen Biotech, INC. | $65.85 | 2022-2024 | Stelara, Tremfya |
| Takeda Pharmaceuticals U.S.A., INC. | $64.78 | 2020-2025 | Entyvio |
| Alk-Abello, INC | $64.33 | 2021 | |
| Lilly USA, LLC | $45.43 | 2023 | Jardiance |
| Novo Nordisk INC | $44.89 | 2023 | Ozempic, Rybelsus |
| Genentech USA, INC. | $36.82 | 2021 | |
| Optinose US, INC. | $31.34 | 2020-2022 | |
| Astrazeneca Pharmaceuticals LP | $29.59 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $28.17 | 2025 | |
| Boston Scientific Corporation | $28.14 | 2024 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $24.32 | 2021 | |
| Merck Sharp & Dohme LLC | $21.90 | 2024 | Dificid |
| Redhill Biopharma INC. | $20.96 | 2023 | Movantik, Aemcolo, Talicia |
| Intercept Pharmaceuticals, INC. | $17.69 | 2021 | |
| Kaleo, INC. | $17.12 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Elena Resnick listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.